Tresiba and Lantus are both long-acting insulins used to manage blood sugar levels in people with type 1 or type 2 diabetes. (For more information on each’s drug uses, see the “What are Tresiba and ...

If you have diabetes, your doctor may prescribe Tresiba. Tresiba is a prescription drug that’s used to manage blood sugar levels. Tresiba is used in adults and some children to treat type 1 or type 2 ...

Tresiba (insulin degludec) is a brand-name drug that’s prescribed for diabetes. The medication is available as a liquid vial and a prefilled injection pen. The cost of Tresiba with and without ...

Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage ...

Dosage for Tresiba (insulin degludec) depends on the type of diabetes (type 1 or type 2) it is prescribed for and other factors. Your doctor may adjust your dosage over the course of your treatment.

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, ...

Diabetics treated with Novo Nordisk’s basal insulin Tresiba have a lower risk of developing low blood sugar compared to Sanofi’s Lantus, according to a new trial. The SWITCH 2 study found that type 2 ...

Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tresiba® (insulin degludec) for the treatment of diabetes. Tresiba® is a new generation of once-daily ...

Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...

Top brands: NovoLog FlexPen ($1.9B); NovoLog ($1.6B); Victoza 3-Pak ($1.4B); Levemir FlexPen ($1.3B) Promotional spend: $564M (13th); 5.4% of rev. R&D spend: $2.0B (15th); down 9.1%; 11.9% of rev.

(RTTNews) - Danish pharmaceutical company Novo Nordisk A/S is recalling 1,468 product samples of Levemir, Tresiba, Fiasp, Novolog and Xultophy to the consumer level, due to improper storage ...

Nov 8 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient ...